11 Aug 2023 --- Synthetic biotechnology pioneer Amyris has filed for bankruptcy in the US, announcing plans to continue operating its consumer brands after they are sold off through retail partners and e-commerce platforms. The company announced that it is moving forward with an operational and financial restructuring to “further advance its ongoing strategic transformation.” Amyris has secured a US$190 million financing commitment from an entity affiliated with existing lender Foris Ventures to support day-to-day operations.
